Skip to content
10-Q

Quarterly Report

MARINUS PHARMACEUTICALS, INC.

0001558370-24-007187

← back to feed
Filed
May 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 54.93M sh
Shares Diluted Q1 2024 · Mar 31, 2024 56.85M sh
Shares Diluted Q1 2024 · Mar 31, 2023 51.77M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$37.46M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$41.48M
Long Term Debt Q1 2024 · Mar 31, 2024 $75M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $104.25M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $120.57M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$16.43M
Stockholders Equity Q1 2024 · Dec 31, 2023 $16.77M
Stockholders Equity Q1 2024 · Mar 31, 2023 $85.09M
Stockholders Equity Q1 2024 · Dec 31, 2022 $116M
Current Liabilities Q1 2024 · Mar 31, 2024 $42.76M
Current Liabilities Q1 2024 · Dec 31, 2023 $40.62M
Total Liabilities Q1 2024 · Mar 31, 2024 $153.78M
Total Liabilities Q1 2024 · Dec 31, 2023 $154.14M
Current Assets Q1 2024 · Mar 31, 2024 $131.28M
Current Assets Q1 2024 · Dec 31, 2023 $165.25M
Total Assets Q1 2024 · Mar 31, 2024 $137.35M
Total Assets Q1 2024 · Dec 31, 2023 $170.91M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.68
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.67
Eps Basic Q1 2024 · Mar 31, 2024 −$0.68
Eps Basic Q1 2024 · Mar 31, 2023 −$0.67
Sga Expense Q1 2024 · Mar 31, 2024 $18.63M
Sga Expense Q1 2024 · Mar 31, 2023 $15.2M
Rd Expense Q1 2024 · Mar 31, 2024 $24.12M
Rd Expense Q1 2024 · Mar 31, 2023 $27.93M
Net Income Q1 2024 · Mar 31, 2024 −$38.67M
Net Income Q1 2024 · Mar 31, 2023 −$34.73M
Operating Income Q1 2024 · Mar 31, 2024 −$35.82M
Operating Income Q1 2024 · Mar 31, 2023 −$32.96M